TNFSF11 and plasma cell myeloma: The identification of the ligand for receptor activator of NFκB (RANKL) [4], [5], [6], and the demonstration that RANKL plays a critical role in normal osteoclast formation [7], raises the possibility that abnormal expression of this molecule may stimulate osteoclast formation and bone resorption in myeloma.